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Abstract
Introduction: Our objective was to determine which one of the two function charts available in Spain to calculate
cardiovascular (CV) risk, Systematic COronary Risk Evaluation (SCORE) or Framingham-REgistre GIroní del COR
(REGICOR), should be used in patients with rheumatoid arthritis (RA).
Methods: A series of RA patients seen over a one-year period without history of CV events were assessed. SCORE,
REGICOR, modified (m)SCORE and mREGICOR according to the European League Against Rheumatism (EULAR)
recommendations were applied. Carotid ultrasonography (US) was performed. Carotid intima-media thickness
(cIMT) > 0.90 mm and/or carotid plaques were used as the gold standard test for severe subclinical atherosclerosis
and high CV risk (US+). The area under the receiver operating curves (AUC) for the predicted risk for mSCORE and
mREGICOR were calculated according to the presence of severe carotid US findings (US+).
Results: We included 370 patients (80% women; mean age 58.9 ± 13.7 years); 36% had disease duration of 10
years or more; rheumatoid factor (RF) and/or anticyclic citrullinated peptide (anti-CCP) were positive in 68%; and
17% had extra-articular manifestations. The EULAR multiplier factor was used in 122 (33%) of the patients. The
mSCORE was 2.16 ± 2.49% and the mREGICOR 4.36 ± 3.46%. Regarding US results, 196 (53%) patients were US+.
The AUC mSCORE was 0.798 (CI 95%: 0.752 to 0.844) and AUC mREGICOR 0.741 (95% CI; 0.691 to 0.792). However,
mSCORE and mREGICOR failed to identify 88% and 91% of US+ patients. More than 50% of patients with mSCORE
≥1% or mREGICOR >1% were US+.




Rheumatoid arthritis (RA) is a condition associated with
high risk for cardiovascular (CV) morbidity and mortality
[1] due to a process of accelerated atherosclerosis [2]. It is
the result of a compound effect mediated by the influence
of genetic and classic CV risk factors along with inflamma-
tion [3,4]. In this regard, a chronic proinflammatory state
is of pivotal importance to accentuate the role of classic
CV risk factors [5]. Strong evidence reveals that chronic
inflammatory markers are independently associated with
CV mortality and morbidity in RA [6-9].
CV disease, especially ischemic heart disease, is one of
the most frequent causes of death in Spain [10]. Neverthe-
less, the incidence of CV disease in general and of
ischemic coronary heart disease in particular is lower than
in other countries [11].
Based on a pool of datasets from 12 European cohort
studies, mainly carried out in general population settings,
European experts performed the Systematic COronary
Risk Evaluation (SCORE) project to develop a risk scoring
system for use in the clinical management of CV risk in
European clinical practice [12]. The SCORE system
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estimates the 10-year risk of a first fatal atherosclerotic
event, including heart attack, stroke or other occlusive
arterial disease and sudden cardiac death. Risk estimates
have been produced as charts for high and low risk regions
in Europe [12]. Spain was included in the low risk group.
In the Spanish population, like in other European
countries, a high CV risk has been defined by a SCORE
of ≥ 5%.
Framingham algorithms have also proved to be extre-
mely useful tools for screening patients and in primary
prevention in countries with a high incidence of coronary
and CV disease [13]. However, they were found to overes-
timate the risk of coronary heart disease in some countries
[14]. Therefore, a validated methodology to adapt the
Framingham algorithm to each specific country was devel-
oped [15]. Currently, in Spain, apart from the SCORE
function, there is another function to estimate the pre-
sence of high CV risk: the Framingham-REgistre GIroní
del COR (REGICOR) calibrated function [16]. The VERI-
FICA study (Validation of the Adapted Framingham
Individual Coronary Incident Risk Algorithm) demon-
strated the reliability and precision of the REGICOR adap-
tation in Spain [17]. A high CV risk has been defined by a
REGICOR of ≥ 10%.
Adequate stratification of the CV risk is an issue of
major importance in patients with RA. A task force of the
European League Against Rheumatism (EULAR) has
recommended a CV risk assessment using National
Guidelines for all RA patients on an annual basis [18].
In the absence of National Guidelines, the SCORE func-
tion model is recommended. Additionally, to address the
excess risk of patients presenting with RA, the experts of
the task force proposed to adapt the CV risk by the appli-
cation of a multiplier factor of 1.5 in those patients with
two of the following three criteria: disease duration of >10
years, rheumatoid factor (RF) or anticyclic citrullinated
peptide (anti-CCP) antibody positivity, and the presence of
certain extra-articular manifestations.
Several validated non-invasive imaging techniques are
currently available to determine subclinical atherosclerosis.
They can offer a unique opportunity to study the relation
of surrogate markers to the development of atherosclero-
sis. Among them, by the assessment of carotid intima-
media thickness (cIMT) and the presence of plaques, caro-
tid ultrasonography (US) has become an affordable
efficient technique to measure the presence of subclinical
atherosclerosis in RA [19,20].
In the general population, cIMT was independently
associated with future risk of ischemic coronary events
and stroke in middle-aged and older individuals. Further-
more, the finding of an atherosclerotic plaque increased
the predicted coronary artery disease risk at any level of
cIMT [21-24].
Increased cIMT and increased frequency of plaques have
been found in patients with RA, even in selected patients
without classic CV risk factors [25,26]. In keeping with the
results observed in the general population, cIMT was
found to predict the development of CV events in RA. In
this regard, RA patients without classic CV risk factors at
the time of the US assessment who had cIMT values
greater than 0.90 mm had increased risk of suffering CV
events over a five-year follow-up period [27]. Evans et al.
also confirmed the implication of carotid plaques as pre-
dictors of future CV events in RA. They found a 2.5
increased risk of CV complications among RA patients
with unilateral plaques, and 4.3 among those with bilateral
plaques [28]. These results highlight the potential role of
carotid US as a predictor of high CV risk in RA.
Taking these considerations together, we designed a
study to establish which one of the two function charts
available in Spain to calculate the CV risk, SCORE or
REGICOR, should be used in patients with RA, taking
as the gold standard test the result of carotid US.
Materials and methods
Patients and study protocol
A set of 370 consecutive Spanish patients with a diagnosis
of RA recruited from Hospital Universitario Marqués de
Valdecilla (Santander, Spain), who were assessed for caro-
tid US over a one-year period, were included in the
present study [29]. All the patients fulfilled the 1987
American College of Rheumatology classification criteria
for RA and also fulfilled the 2010 classification criteria for
RA [30,31]. Patients with a history of CV events (ischemic
heart disease, cerebrovascular accident, peripheral arterial
disease or heart failure) were excluded from the study.
Then, clinical records of all patients were again reviewed
in an attempt to fully establish comorbidities.
A subject’s written consent was obtained in all the
cases. The study was approved by the Ethical Commit-
tee of the Hospital Universitario Marqués de Valdecilla
(Ethical Committee of Cantabria, Spain).
CV risk assessment
The SCORE CV risk index was calculated according to
data on the age at the time of the study, sex, smoking his-
tory, the systolic arterial blood pressure and atherogenic
index (total serum cholesterol level/high density lipopro-
tein serum (HDL) cholesterol). In parallel, the REGICOR
CV risk index was calculated with age, sex, total choles-
terol and HDL-cholesterol, systolic and diastolic arterial
blood pressure, and history of diabetes mellitus and
smoking.
Both modified (m)SCORE and mREGICOR were
calculated according to the EULAR recommendations,
as described above [18].
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Carotid US examination
Carotid US examination included the measurement of
cIMT in the common carotid artery and the detection of
focal plaques in the extracranial carotid tree. A commer-
cially available scanner, Mylab 70, Esaote (Genoa, Italy)
equipped with a 7 to 12 MHz linear transducer and the
automated software guided technique radiofrequency -
Quality Intima Media Thickness in real-time (QIMT,
Esaote, Maastricht, The Netherlands) - was used [29]. The
plaque criteria in the accessible extracranial carotid tree
(common carotid artery, bulb and internal carotid artery)
were focal protrusion in the lumen at least cIMT > 1.5
mm, protrusion at least 50% greater than the surrounding
cIMT, or arterial lumen encroaching > 0.5 mm, according
to the Mannheim consensus criteria [32]. Carotid plaques
were counted in each territory and defined as no plaque,
unilateral plaque or bilateral plaques. We considered
cIMT > 0.90 mm and/or carotid plaques as the gold stan-
dard for severe subclinical atherosclerosis [29]. For the
purpose of the present study, patients with any of these
severe US findings were defined as US+.
Statistical analysis
Results were expressed as number (percentage) or mean
± standard deviation (SD).
The area under the receiver operating curve (AUC) for
the predicted risk both by mSCORE and mREGICOR was
calculated according to the presence of severe carotid US
findings (US+).
Using the same gold standard, we also calculated the
sensitivity, specificity, positive predictive value and nega-
tive predictive value for each integer between 1% and 5%
for mSCORE and between 1% and 10% for mREGICOR.
All statistical tests were performed with the package
Stata V.12/SE (Stata Corp, College Station, TX, USA).
Results
Most patients from this series of 370 patients without CV
events were women (298; 80%). The age at the time of the
study and disease duration was 58.9 ± 13.7 and 9.8 ± 8.3
years, respectively. One hundred thirty-four patients (36%)
had a disease duration of ≥10 years; RF and/or anti-CCP
positivity were found in 250 (68%) cases; a total of 61
subjects (17%) had extra-articular manifestations (nodular
disease in 24 patients, secondary Sjögren’s syndrome in 21,
pleuritis/pericarditis in 8, pulmonary fibrosis in 7,
Raynaud’s phenomenon in 3, rheumatoid vasculitis in 2,
scleritis/episcleritis in 2, sclerosing cholangitis in 1 case
and Felty’s syndrome in 1 case).
The EULAR multiplier factor was required to be used in
122 (33%) of the patients. Due to this, the mSCORE was
2.16 ± 2.49% and the mREGICOR, 4.36 ± 3.46%. Regard-
ing US results, cIMT >0.90 mm was observed in 46 (12%)
patients and carotid plaques in 195 (53%). Interestingly, 45
of the 46 patients with cIMT >0.90 also had carotid
plaques. According to our previous definition, 196 (53%)
patients were US+.
Although the values of the area under the receiver oper-
ating curves of both functions in their modified versions -
AUC mSCORE: 0.798 (CI 95%: 0.752 to 0.844) and AUC
mREGICOR: 0.741 (CI 95%; 0.691 to 0.792) (Figure 1)
were promising with respect to their discriminating capa-
city, the behavior of both functions in the identification of
the patients with subclinical atherosclerosis and, therefore,
high CV risk was disappointing. In this regard, the
mSCORE and the mREGICOR only classified 11% and 6%
as patients with high CV risk, respectively. Inversely,
mSCORE and mREGICOR misclassified as having high
CV risk 4% and 2% of the patients without subclinical
atherosclerosis. Also, the mSCORE and the mREGICOR
failed to classify as having high CV risk 82% and 91% of
the patients, respectively. Therefore, neither of these two
functions to estimate CV risk was proved to be effective in
Spanish RA patients.
More than 50% of patients with an mSCORE ≥ 1% or
mREGICOR > 1% had US+. In consequence, to disclose
the presence of severe subclinical atherosclerotic disease
in at least 50% of these patients, carotid US would have to
be performed on 73% and 86% of them, respectively.
In Table 1, we describe the sensitivity, specificity, posi-
tive predictive value and negative predictive value for each
integer between 1% and 5% for mSCORE and between 1%
and 10% for mREGICOR.
Since many rheumatologists do not have access to
carotid US in their daily clinical practice, we tried to find
the CV risk threshold that may be useful in indicating
Figure 1 Area under the receiver operating curves for the
predicted CV risk by mSCORE and mREGICOR according to the
established gold standard (US+). CV, cardiovascular; mREGICOR,
modified Framingham-REgistre GIroní del COR; mSCORE, modified
Systematic COronary Risk Evaluation; US, ultrasound
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high risk and, therefore, the need of a lipid lowering or an
antihypertensive treatment.
Patients with type 1 diabetes with target organ damage,
type 2 diabetes mellitus or those who have severe chronic
kidney disease are considered as having very high CV risk
according to current guidelines, regardless yof chart
function results [24]. Forty three patients from this series
had type 2 diabetes or chronic renal disease and were
excluded from further analyses. Interestingly, 34 (79%) of
them also had severe US findings, that is, US+.
When we used lower thresholds of mSCORE and mRE-
GICOR than those usually recommended in the 327 RA
patients without diabetes or severe chronic kidney disease,
we increased the number of patients classified as having
high CV. Using a threshold of 3% for mSCORE or 4% for
mREGICOR, we identified more than 50% of US+
patients, even at the risk of misclassification as high CV
risk in 20 to 30% of the patients without severe subclinical
atherosclerosis. Specifically, an mSCORE ≥ 3% classified
correctly as having high CV risk in 55% of patients and
incorrectly in 18% of patients. Likewise, an mREGICOR
≥ 4% classified as having high CV correctly in 63% of
patients and incorrectly in 30% of patients.
Discussion
Comparisons between SCORE and REGICOR did not
disclose that one of them might be better than the other
in establishing the CV risk in Spanish individuals without
rheumatic diseases [33-37]. In the present study, neither
mSCORE nor mREGICOR were shown to be effective in
the stratification of the CV risk of Spanish RA patients. In
this regard, when CV risk was defined by the presence of
carotid subclinical atherosclerosis, we observed that both
CV risk function charts identified a very low proportion of
RA patients with high CV risk and misclassified as having
high CV risk a substantial proportion of the patients with-
out subclinical atherosclerosis. Nevertheless, SCORE
and REGICOR predict CV mortality and CV events,
respectively, and none of them has been tested for the
prediction of subclinical atherosclerosis. In addition, these
two CV risk function charts have been designed to detect
more than just atherosclerotic disease. Therefore, some of
the apparently misclassified patients might not truly be
misclassified if other CV outcomes were considered in this
study.
This study has some limitations. First, actual CV
events and mortality were not available and carotid US
was used as a surrogate marker of CV risk. Second, our
results cannot be generalized to other populations
within and outside Spain.
Several years ago, del Rincon et al. stated that physi-
cians who provide care to individuals with RA should be
aware of the increased risk of CV events in these patients
and implement appropriate diagnostic and therapeutic
measures [38]. More recently, Crowson and Gabriel
emphasized that the CV risk assessment tools designed
for the general population may not accurately estimate
the CV risk for individual patients with RA, even if the
multiplication factor indicated by the EULAR task force
is applied [39]. These authors concluded that although in
some circumstances patients with RA satisfying the cri-
teria for use of the multiplier factors may have increased
risk of CV disease, some others that do not meet these
criteria may also have increased CV risk [39].
Table 1 Sensitivity, specificity, positive predictive value and negative predictive value for each integer between 1%
and 5% for mSCORE and between 1% and 10% for mREGICOR
Threshold Sensibility Specificity Positive predictive value Negative predictive value
mSCORE ≥1% (n: 271) 0.939 0.500 0.679 0.879
≥2% (n: 174) 0.679 0.764 0.764 0.679
≥3% (n: 125) 0.510 0.856 0.800 0.608
≥4% (n: 66) 0.281 0.937 0.833 0.536
≥5% (n: 45) 0.179 0,966 0.854 0.511
mREGICOR ≥1% (n: 355) - 0.058 0.541 -
≥2% (n: 299) 0.958 0.335 0.615 0.879
≥3% (n: 233) 0.802 0.543 0.661 0.712
≥4% (n: 168) 0.620 0.717 0.708 0.629
≥5% (n: 117) 0.443 0.815 0.726 0.569
≥6% (n: 90) 0.349 0.867 0.744 0.545
≥7% (n: 63) 0.250 0.913 0.762 0.523
≥8% (n: 43) 0.177 0.948 0.791 0.509
≥9% (n: 35) 0.151 0.965 0.829 0.506
≥10% (n: 21) 0.094 0.983 0.857 0.495
mREGICOR, modified Framingham-REgistre GIroní del COR; mSCORE, modified Systematic COronary Risk Evaluation
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A good method of predicting CV events would allow us
to establish a high risk threshold to identify, with high
sensitivity and specificity, those patients who have a high
probability of presenting a CV event; and also a low risk
threshold below which we could establish a very low
probability of having a CV event. With the help of these
two thresholds, we would have to set up a strategy consist-
ing of an indication of therapy to patients who are above
the threshold of high CV risk, no specific therapy to those
patients who are below the low risk threshold, and the
need for performing a diagnostic test in those patients
included in the category of moderate/intermediate risk.
Recent studies indicate that carotid US may be a useful
diagnostic tool to disclose subclinical atherosclerosis [29],
but universal screening is not always feasible in many
rheumatology clinics. Therefore, it would be interesting to
define a CV risk threshold above which the indication of
intensive lipid lowering or antihypertensive treatment was
required in patients with RA.
Patients with type 1 diabetes with target organ damage,
type 2 diabetes mellitus or those with severe chronic kid-
ney disease (if glomerular filtration rate <60 ml/min/1.73
m2) are considered as having very high CV risk according
to current guidelines [24]. In keeping with that, 79% of the
RA patients with diabetes or severe kidney disease of our
study were US+. Therefore, these patients are considered
as having high CV risk and, because of that, non-invasive
techniques used to detect the presence of subclinical
atherosclerosis would not be required in these patients.
According to our present results, in the remaining
patients, SCORE and REGICOR do not seem to be useful
in identifying RA Spanish patients with subclinical athero-
sclerosis and increased CV risk.
Conclusions
Neither of the two function charts used in Spain to esti-
mate the CV risk in the general population proved to be
effective in stratifying the CV risk in patients with RA.
Nevertheless, further assessment of the accuracy of the
SCORE to identify high CV risk RA patients is needed
in other populations.
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